

IN THE CLAIMS

Listing of Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently amended) A dry powder formulation for inhalation, comprising active particles and carrier particles for supporting the active particles, the formulation-further ~~containing~~ comprising magnesium stearate in an amount of at least 0.5% by weight of the formulation, and wherein particles of magnesium stearate are disposed on the surface of the carrier particles to provide a surface coverage of less than 10% on the carrier particles. ~~such that the surface coverage of carrier particles is less than 10%.~~
2. (Currently amended) ~~[[A]]~~ The dry powder formulation according to claim 1, wherein the surface coverage of carrier particles is from 1 to 5%.
3. (Currently amended) ~~[[A]]~~ The dry powder formulation according to claim 1, ~~or claim 2~~ wherein the magnesium stearate is present in amounts of 0.5 to 2% by weight.
4. (Currently amended) ~~[[A]]~~ The dry powder formulation according to ~~any of the preceding claims~~ claim 1, wherein the magnesium stearate is present in amounts of from 0.6 to 1% by weight.
5. (Currently amended) ~~[[A]]~~ The dry powder formulation according to ~~any of the preceding claims~~ claim 1, wherein the active particles comprise an active substance ~~[[is]]~~ selected from the group consisting of beta-mimetics, anticholinergics, corticosteroids, leukotrienantagonists, phosphodiesterase inhibitors, PAF-inhibitors, potassium channel openers, analgesics, potency agents, macromolecules, pharmaceutically acceptable salts thereof and mixtures thereof. ~~selected from Levalbuterol, Terbutalin, Reproterol, Salbutamol, Salmeterol,~~

~~Formoterol, Fenoterol, Clenbuterol, Bambuterol, Tulobuterol, Broxaterol, Epinephrin, Isoprenaline or Hexoprenaline; Anticholinergic selected from Tiotropium, Ipratropium, Oxitropium or Glycopyrronium; Corticosteroids, selected from Butixocart, Rofleponide, Budesonide, Ciclesonide, Mometasone, Fluticasone, Beclomethasone, Loteprednol or Triamcinolone; Leukotrienantagonists, selected from Andolast, Iralukast, Pranlukast, Imitrodast, Seratrodast, Zileuton, Zafirlukast or Montelukast; Phosphodiesterase Inhibitors, selected from Filaminast or Piclamilast; PAF Inhibitors, selected from Apafant, Forapafant or Israpafant; potassium channel opener selected from Amiloride or Furosemide; analgesics (pain killers) selected from Morphine, Fentanyl, Pentazocine, Buprenorphine, Pethidine, Tilidine, Methadone or Heroin; potency agents selected from Sildenafil, Alprostadil or Phentolamine; pharmaceutically acceptable derivative or salt of any of the foregoing compounds or classes of compounds; and macromolecules selected from proteins, peptides, oligopeptides, polypeptides, polyamino acids, nucleic acids, polynucleotides, oligo-nucleotides and high molecular weight polysaccharides.~~

6. (Currently amended) ~~[[A]]~~ The dry powder formulation according to claim 1, any of the preceding claims wherein the carrier particles comprise a carrier material ~~[[is]]~~ selected from ~~[[a]]~~ monosaccharides, disaccharides, sugar alcohols, polylactic acid, or mixtures thereof. ~~mono- or di-saccharides such as glucose, lactose, lactose mono-hydrate, sucrose or trehalose; sugar alcohols such as mannitol or xylitol; polylactic acid; or mixtures thereof.~~

7. (Currently amended) ~~[[A]]~~ The dry powder formulation according to claim 6, any of the preceding claims wherein the carrier is lactose mono-hydrate.

8. (Currently amended) A method of making ~~[[a]]~~ the dry powder formulation for inhalation according to claim 1, as claimed in any one of claims 1 to 7 comprising the step of blending magnesium stearate with a carrier material in a diffusion blender for a period of less than 30 minutes to form a mixture.

9. (Currently amended) ~~[[A]] The method according to claim 8, further comprising the step of: making a dry powder for inhalation as claimed in claim 8 consisting of the consecutive steps of:-~~

- ~~(i) magnesium stearate with a carrier material in a diffusion blender for a period of less than 30 minutes;~~
- ~~(ii) blending the mixture of magnesium stearate and carrier material step (i) with an active substance in a diffusion blender for a period of less than 30 minutes.~~

10. (Currently amended) A multi-dose dry powder inhaler containing ~~[[a]] the formulation according to claim 1. as defined in any of the claims 1 to 7.~~

11. (New) A method of making a dry powder consisting essentially of the consecutive steps of:

- (i) admixing magnesium stearate with a carrier material in a diffusion blender for a period of less than 30 minutes; and
- (ii) blending the mixture of step (i) with an active substance in a diffusion blender for a period of less than 30 minutes.

12. (New) The dry powder formulation according to claim 5, wherein the beta-mimetic is selected from the group consisting of Levalbuterol, Terbutalin, Reproterol, Salbutamol, Salmeterol, Formoterol, Fenoterol, Clenbuterol, Bambuterol, Tulobuterol, Broxaterol, Epinephrin, Isoprenaline and Hexoprenaline.

13. (New) The dry powder formulation according to claim 5, wherein the anticholinergic is selected from the group consisting of Tiotropium, Ipratropium, Oxitropium and Glycopyrronium.

14. (New) The dry powder formulation according to claim 5, wherein the corticosteroid is selected from the group consisting of Butixocart, Rofleponide, Budesonide, Ciclosenide, Mometasone, Fluticasone, Beclomethasone, Loteprednol and Triamcinolone.

15. (New) The dry powder formulation according to claim 5, wherein the leukotrienantagonist is selected from the group consisting of Andolast, Iralukast, Pranlukast, Imitrodest, Seratrodest, Zileuton, Zafirlukast and Montelukast.

16. (New) The dry powder formulation according to claim 5, wherein the phosphodiesterase-inhibitor is selected from Filaminast or Piclamilast.

17. (New) The dry powder formulation according to claim 5, wherein the PAF-inhibitor is selected from the group consisting of Apafant, Forapafant and Israpafant.

18. (New) The dry powder formulation according to claim 5, wherein the potassium channel opener is selected from Amiloride or Furosemide.

19. (New) The dry powder formulation according to claim 5, wherein the analgesic is selected from the group consisting of Morphine, Fentanyl, Pentazocine, Buprenorphine, Pethidine, Tilidine, Methadone and Heroin.

20. (New) The dry powder formulation according to claim 5, wherein the potency agent is selected from the group consisting of Sildenafil, Alprostadil and Phentolamine.

21. (New) The dry powder formulation according to claim 5, wherein the macromolecule is selected from the group consisting of proteins, peptides, oligopeptides, polypeptides, polyamino acids, nucleic acids, polynucleotides, oligo-nucleotides and high molecular weight polysaccharides.

Applicant(s): Rudi Mueller-Walz. *et al.*
Serial No.: To Be Assigned
Filing Date: April 14, 2006
Title: "Dry Powder Formulations"
Page -6-

Docket No.: 28069-625-NATL

22. (New) The dry powder formulation according to claim 6, wherein the monosaccharide or disaccharide is selected from the group consisting of glucose, lactose, lactose monohydrate, sucrose, trehalose and mixtures thereof.

23. (New) The dry powder formulation according to claim 6, wherein the sugar alcohol is selected from mannitol, xylitol, or a mixture thereof.

Express Mail Label No: EV532354025US